Foamix Pharmaceuticals Ltd (FOMX)

[Whos_Who]

Foamix to Present Late Breaking Data at the 77th Annual Meeting of the Society for Investigative Dermatology

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix" or the "Company"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced it will present two late-breaking posters relating to its topical product candidate FMX101, a 4% minocycline foam being developed for the treatment of moderate-to-severe acne, at the 77th Annual Meeting of the Society for Investigative Dermatology to be held May 8-11, 2019, in Chicago, Illinois. Foamix previously announced that the U.S. Food & Drug Administration (FDA) has accepted the filing of a New Drug Application for FMX101 for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients nine years of age and older and the FDA has set an action date of October 20, 2019 under the Prescription Drug User Fee Act (PDUFA).

Poster Presentation Details:

Title: The Impact of FMX101 on the Physical Properties of Human Sebum: Comparison of an Oil-Based Formulation vs an Oil-in-Water Emulsion

Poster Number: LB1118

Authors: Yohan Hazot; Lenny Margulis, PhD; Shay Burban; Russell Elliott, PhD; Iain Stuart, PhD

Poster Session I; Thursday May 9, 2019; 10:45 am - 12:45 pm Central Time

Location: Late-breaking posters LB 1046 - LB 1144

Title: Assessing Bacterial Susceptibility of FMX101 4% Topical Minocycline Foam

Poster Number: LB1117

Authors: Joyce Sutcliffe, PhD; Robert McLaughlin, PhD; James Del Rosso, DO; Jonathan Weiss, MD; Hilary Baldwin, MD; Guy Webster, MD PhD; James Leyden, MD; Xilin Zhao, PhD; Andrew Read, PhD; Karl Drlica, PhD; Russell Elliott, PhD; Iain Stuart, PhD

Poster Session II; Friday, May 10, 2019; 11:15 am - 1:15 pm Central Time

Location: Late-breaking posters LB 1047 - LB 1143

Members of the Foamix R&D team will be on-site at the conference to present the research in these sessions. Research abstracts will also be published in the Journal of Investigative Dermatology this fall and will be available as handouts at the SID 2019 meeting.

About the Society for Investigative Dermatology (SID) and the SID Annual Meeting

The Mission of the Society for Investigative Dermatology (SID) is to advance and promote scientific evidence relevant to skin health and disease through education and scholarly exchange of scientific information, with the intent to foster improvement in the competence (abilities, skills and strategies) of dermatology researchers and clinicians.

The 77th Annual Meeting of the SID is a forum in which a diverse community of scientists comes to exchange information on the latest advances. The SID Annual Meeting draws a diverse group of senior researchers and clinicians, as well as hundreds of clinical trainees including dermatology residents. These healthcare professionals and basic researchers are on the frontline for recognizing systemic disease (including many types of cancer) with a skin-related association. For additional information, visit https://www.sidannualmeeting.org/.